| Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study S Blach, S Zeuzem, M Manns, I Altraif, AS Duberg, DH Muljono, I Waked, ... The lancet Gastroenterology & hepatology 2 (3), 161-176, 2017 | 2179 | 2017 |
| Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study P Marcellin, E Gane, M Buti, N Afdhal, W Sievert, IM Jacobson, ... The Lancet 381 (9865), 468-475, 2013 | 2159 | 2013 |
| Adefovir dipivoxil for the treatment of hepatitis B e antigen–positive chronic hepatitis B P Marcellin, TT Chang, SG Lim, MJ Tong, W Sievert, ML Shiffman, ... New England Journal of Medicine 348 (9), 808-816, 2003 | 2051 | 2003 |
| Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study D Razavi-Shearer, I Gamkrelidze, MH Nguyen, DS Chen, P Van Damme, ... The lancet Gastroenterology & hepatology 3 (6), 383-403, 2018 | 1657 | 2018 |
| Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine DJ Tenney, SM Levine, RE Rose, AW Walsh, SP Weinheimer, L Discotto, ... Antimicrobial agents and chemotherapy 48 (9), 3498-3507, 2004 | 789 | 2004 |
| A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt W Sievert, I Altraif, HA Razavi, A Abdo, EA Ahmed, A AlOmair, ... Liver international 31, 61-80, 2011 | 702 | 2011 |
| The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm H Razavi, I Waked, C Sarrazin, RP Myers, R Idilman, F Calinas, W Vogel, ... Journal of viral hepatitis 21, 34-59, 2014 | 562 | 2014 |
| Long‐term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen–positive chronic hepatitis B P Marcellin, TT Chang, SGL Lim, W Sievert, M Tong, S Arterburn, ... Hepatology 48 (3), 750-758, 2008 | 522 | 2008 |
| Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study S Blach, NA Terrault, F Tacke, I Gamkrelidze, A Craxi, J Tanaka, I Waked, ... The Lancet Gastroenterology & Hepatology 7 (5), 396-415, 2022 | 483 | 2022 |
| All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study M Manns, S Pol, IM Jacobson, P Marcellin, SC Gordon, CY Peng, ... The Lancet 384 (9954), 1597-1605, 2014 | 456 | 2014 |
| Historical epidemiology of hepatitis C virus (HCV) in selected countries P Bruggmann, T Berg, ALH Øvrehus, C Moreno, CE Brandão Mello, ... Journal of viral hepatitis 21, 5-33, 2014 | 416 | 2014 |
| Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 … E Lawitz, E Gane, B Pearlman, E Tam, W Ghesquiere, D Guyader, L Alric, ... The Lancet 385 (9973), 1075-1086, 2015 | 382 | 2015 |
| STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation H Tye, CL Kennedy, M Najdovska, L McLeod, W McCormack, N Hughes, ... Cancer cell 22 (4), 466-478, 2012 | 322 | 2012 |
| Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis with Telbivudine or Adefovir: A Randomized Trial HLY Chan, EJ Heathcote, P Marcellin, CL Lai, M Cho, YM Moon, ... Annals of internal medicine 147 (11), 745-754, 2007 | 279 | 2007 |
| Strategies to manage hepatitis C virus (HCV) disease burden H Wedemeyer, AS Duberg, M Buti, WM Rosenberg, S Frankova, G Esmat, ... Journal of viral hepatitis 21, 60-89, 2014 | 278 | 2014 |
| Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B SJ Patterson, J George, SI Strasser, AU Lee, W Sievert, AJ Nicoll, ... Gut 60 (2), 247-254, 2011 | 234 | 2011 |
| Global multi-stakeholder endorsement of the MAFLD definition N Méndez-Sánchez, E Bugianesi, RG Gish, F Lammert, H Tilg, ... The lancet Gastroenterology & hepatology 7 (5), 388-390, 2022 | 222 | 2022 |
| Transplantation of Human Amnion Epithelial Cells Reduces Hepatic Fibrosis in Immunocompetent CCl4-Treated Mice U Manuelpillai, J Tchongue, D Lourensz, V Vaghjiani, CS Samuel, A Liu, ... Cell transplantation 19 (9), 1157-1168, 2010 | 215 | 2010 |
| Amnion epithelial cell-derived exosomes restrict lung injury and enhance endogenous lung repair JL Tan, SN Lau, B Leaw, HPT Nguyen, LA Salamonsen, MI Saad, ... Stem cells translational medicine 7 (2), 180-196, 2018 | 212 | 2018 |
| Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial JM Llovet, M Kudo, P Merle, T Meyer, S Qin, M Ikeda, R Xu, J Edeline, ... The lancet oncology 24 (12), 1399-1410, 2023 | 208 | 2023 |
